ABOUT SEEKYO
SEEKYO® is a privately-owned biotech company developing the next generation of chemotherapies, providing cancer patient efficient treatment without adverse effects.
We are designing smart drugs that selectively target the microenvironment of solid tumors while sparing healthy tissues.
Chemotherapy is one of the main therapeutic option for cancer patients.
However, most anticancer drugs used clinically lack any intrinsic selectivity, causing severe side effects as the result of their toxicity toward healthy tissues.
Chemotherapy is one of the main therapeutic option for cancer patients.
However, most anticancer drugs used clinically lack any intrinsic selectivity, causing severe adverse effects as the result of their toxicity toward healthy tissues
With the aim of offering improved treatments to cancer patients, SEEKYO‘s therapeutic vectors are
SEEKYO®’s unique technology comprises a molecular platform enabling the custom design of almost any type of therapeutic vector.
This versatile linker technology offers the possibility to design “on demand” the most appropriate targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.
SEEKYO®’s self-immolative linker can gather in a single molecular entity:
Step 1. SKY 01 binds covalently to circulating albumin leading to the formation of the bioconjugate
Step 2. The bioconjugate accumulates in the tumor microenvironment where enzymatic activation triggers the release of the drug molecules.
Step 3. The drugs penetrate inside surrounding cancer cells to exert their anticancer activity.
The versatility of the technology allows:
DRUG DEVELOPMENT
The development of the next generation of
smart therapeutic vectors targeting the
microenvironment’s hallmarks
INDUSTRIAL COLLABORATION
In optimizing the efficacy of current
Antibody Drug Conjugates (ADC)
.
SCIENTIFIC ADVISORY BOARD
